

Company Number: 400098

Leaside Pharmacy Limited
Abridged Unaudited Financial Statements
for the financial year ended 31 August 2025

Leaside Pharmacy Limited

CONTENTS

	Page
Director's Responsibilities Statement	3
Balance Sheet	4 - 5
Reconciliation of Shareholders' Funds	6
Notes to the Financial Statements	7 - 10

Leeside Pharmacy Limited

DIRECTOR'S RESPONSIBILITIES STATEMENT

for the financial year ended 31 August 2025

The director made the following statement in respect of the unaudited financial statements:

"General responsibilities

The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the director to prepare financial statements for each financial year. Under that law, the director has elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the director must not approve the financial statements unless she is satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the director is required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable her to ensure that the financial statements and Director's Report comply with the Companies Act 2014. She is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Director's declaration on unaudited financial statements

In relation to the financial statements which comprise the Balance Sheet, the Reconciliation of Shareholders' Funds and the related notes:

The director approves these financial statements and confirms that she is responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The director confirms that she has made available to Denis Breen & Co Limited, all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The director confirms that to the best of her knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 31 August 2025."

Signed on behalf of the board

Mr. Cormac Deasy
Director

2 April 2026

Leaside Pharmacy Limited
BALANCE SHEET

as at 31 August 2025

	Notes	2025 €	2024 €
Fixed Assets			
Tangible assets	7	<u>217,069</u>	<u>206,904</u>
Current Assets			
Stocks	8	76,445	76,763
Debtors	9	462,169	495,059
Cash and cash equivalents		<u>416,611</u>	<u>259,908</u>
		<u>955,225</u>	<u>831,730</u>
Creditors: amounts falling due within one year	10	<u>(117,911)</u>	<u>(123,861)</u>
Net Current Assets		<u>837,314</u>	<u>707,869</u>
Total Assets less Current Liabilities		<u><u>1,054,383</u></u>	<u><u>914,773</u></u>
Capital and Reserves			
Called up share capital presented as equity		1,000	1,000
Retained earnings		<u>1,053,383</u>	<u>913,773</u>
Equity attributable to owners of the company		<u><u>1,054,383</u></u>	<u><u>914,773</u></u>

Leeside Pharmacy Limited

BALANCE SHEET

as at 31 August 2025

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

I as Director of Leeside Pharmacy Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) I acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 2 April 2026 and signed on its behalf by:

Mr. Cormac Deasy
Director

Leaside Pharmacy Limited
RECONCILIATION OF SHAREHOLDERS' FUNDS

as at 31 August 2025

	Called up share capital €	Retained earnings €	Total €
At 1 September 2023	1,100	803,946	805,046
Profit for the financial year	-	109,827	109,827
Redemption of equity shares	(100)	-	(100)
At 31 August 2024	1,000	913,773	914,773
Profit for the financial year	-	139,610	139,610
At 31 August 2025	1,000	1,053,383	1,054,383

Leeside Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 August 2025

1. General Information

Leeside Pharmacy Limited is a company limited by shares incorporated in Ireland. The registered office of the company is Coachford Pharmacy, Coachford, Cork. The Company's principal activity is the operation of a retail pharmacy. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the year ended 31 August 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Land	-	No Depreciation
Premises	-	2% Straight line
Fixtures, fittings and equipment	-	12.5% Straight line
Motor vehicles	-	12.5% Straight line
Computer Equipment	-	12.5% Straight line

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Leaside Pharmacy Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 31 August 2025

Employee benefits

Short term benefits, including holiday pay and other non-monetary benefits, are recognised as an expense in the period in which the service is received.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

Government grants

Capital grants received and receivable are treated as deferred income and amortised to the Profit and Loss Account annually over the useful economic life of the asset to which it relates. Revenue grants are credited to the Profit and Loss Account when received.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Operating profit	2025	2024
	€	€
Operating profit is stated after charging/(crediting):		
Depreciation of tangible assets	8,101	7,614
Government grants received	(4,000)	-
	<u> </u>	<u> </u>
4. Other Gains and Losses	2025	2024
	€	€
Fair value gains and losses are as follows:		
Investment property	-	7,178
	<u> </u>	<u> </u>
5. Interest payable and similar expenses	2025	2024
	€	€
On amounts payable to group companies	939	-
	<u> </u>	<u> </u>
6. Employees		

The average monthly number of employees, including director, during the financial year was 13, (2024 - 14).

Leaside Pharmacy Limited
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 August 2025

7. Tangible assets

	Land	Premises	Fixtures, fittings and equipment	Motor vehicles	Computer Equipment	Total
	€	€	€	€	€	€
Cost						
At 1 September 2024	129,378	66,032	140,275	52,735	28,639	417,059
Additions	15,595	-	-	-	2,671	18,266
At 31 August 2025	<u>144,973</u>	<u>66,032</u>	<u>140,275</u>	<u>52,735</u>	<u>31,310</u>	<u>435,325</u>
Depreciation						
At 1 September 2024	-	14,528	125,509	52,735	17,383	210,155
Charge for the financial year	-	1,321	3,712	-	3,068	8,101
At 31 August 2025	<u>-</u>	<u>15,849</u>	<u>129,221</u>	<u>52,735</u>	<u>20,451</u>	<u>218,256</u>
Net book value						
At 31 August 2025	<u>144,973</u>	<u>50,183</u>	<u>11,054</u>	<u>-</u>	<u>10,859</u>	<u>217,069</u>
At 31 August 2024	<u><u>129,378</u></u>	<u><u>51,504</u></u>	<u><u>14,766</u></u>	<u><u>-</u></u>	<u><u>11,256</u></u>	<u><u>206,904</u></u>

Leeside Pharmacy Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 31 August 2025

8. Stocks	2025	2024
	€	€
Finished goods and goods for resale	76,445	76,763

The replacement cost of stock did not differ significantly from the figures shown.

9. Debtors	2025	2024
	€	€
Trade debtors	75,194	74,040
Amounts owed by group undertakings	176,000	176,000
Other debtors	122,164	122,164
Director's current account	51,876	99,632
Taxation	32,877	19,421
Prepayments	4,058	3,802
	462,169	495,059

10. Creditors	2025	2024
Amounts falling due within one year	€	€
Trade creditors	91,448	91,348
Taxation	21,363	27,713
Accruals	5,100	4,800
	117,911	123,861

11. Income Statement	2025	2024
	€	€
At 1 September 2024	913,773	803,946
Profit for the financial year	139,610	109,827
At 31 August 2025	1,053,383	913,773

12. Capital commitments
The company had no material capital commitments at the financial year-ended 31 August 2025.

13. Director's remuneration	2025	2024
	€	€
Remuneration	162,500	162,500

14. Post-Balance Sheet Events
There have been no significant events affecting the company since the financial year-end.

15. Approval of financial statements
The financial statements were approved and authorised for issue by the board on 2 April 2026.